| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.006 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.096 | 0.007 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.16 | 0.009 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.009 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.2 | 0.009 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.01 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |